🇺🇸 HUMAN C1-ESTERASE INHIBITOR in United States

1,170 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Hereditary Angioedema — 355 reports (30.34%)
  2. Off Label Use — 188 reports (16.07%)
  3. Drug Ineffective — 132 reports (11.28%)
  4. Product Dose Omission Issue — 90 reports (7.69%)
  5. Inappropriate Schedule Of Product Administration — 78 reports (6.67%)
  6. Weight Increased — 68 reports (5.81%)
  7. Dyspnoea — 67 reports (5.73%)
  8. Product Use Issue — 67 reports (5.73%)
  9. Prescribed Overdose — 64 reports (5.47%)
  10. Fatigue — 61 reports (5.21%)

Source database →

HUMAN C1-ESTERASE INHIBITOR in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is HUMAN C1-ESTERASE INHIBITOR approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for HUMAN C1-ESTERASE INHIBITOR in United States?

Marketing authorisation holder not available in our data.